Navigation Links
K-V Pharmaceutical Use of Cash Collateral Approved by U. S. Bankruptcy Court
Date:8/10/2012

ST. LOUIS, Aug. 10, 2012 /PRNewswire/ -- K-V Pharmaceutical Company ("K-V" or "the Company") announced that the U.S. Bankruptcy Court for the Southern District of New York, the Honorable Judge Allan L. Gropper presiding, today approved on an interim basis the Company's request for the use of cash collateral that was made as part of the Company's voluntary reorganization cases filed under chapter 11 of the U. S. Bankruptcy Code.

"Together with the Court's prior approval of our First Day motions, this authorization of the use of cash collateral is another important step forward, further ensuring that K-V is able to continue operations and focus on the restructuring process," said Greg Divis, President and CEO of K-V Pharmaceutical. "Meanwhile, reaching agreement regarding this matter with our Senior Noteholders sets the stage for continued cooperation toward the development of a plan of restructuring under which K-V will be able to emerge from chapter 11 as a stable and competitive company," Divis concluded.

K-V and certain of its affiliates commenced cases to reorganize under chapter 11 of the U.S. Bankruptcy Code on August 4, 2012. The chapter 11 cases are being jointly administered under case number 12-13346. 

As a further step along the path of its restructuring, the Office of the United States Trustee will hold a meeting to form an Official Committee of Unsecured Creditors on August 13, 2013. Final hearings on the First Day motions, certain other motions as well as a final hearing on the use of cash collateral are scheduled for August 23, 2012.

Updates and additional information can be found at the Company's website www.kvph.com .  In addition, the Company's Claims Administrator, Epiq Bankruptcy Solutions, Inc., maintains a web-based resource where documents from the chapter 11 cases, including the Company's Petitions, can be found, http://dm.epiq
'/>"/>

SOURCE K-V Pharmaceutical Company
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. MAP Pharmaceuticals to Present at Upcoming Investor Conferences
2. Avanir Pharmaceuticals Reports Fiscal 2012 Third Quarter Financial And Business Results
3. K-V Pharmaceutical "First Day" Motions Approved by U.S. Bankruptcy Court
4. Savient Pharmaceuticals Reports Second Quarter 2012 Financial Results
5. Auxilium Pharmaceuticals, Inc. to Present at the Canaccord Genuity 32nd Annual Growth Conference
6. UCF nanoparticle discovery opens door for pharmaceuticals
7. Cadence Pharmaceuticals Reports Second Quarter 2012 Financial Results
8. Inspiration Biopharmaceuticals Expands Industry Expertise with Five New Executive Hires
9. Pharmaceutical, Food Companies Find Presswood Pallet Ideal for BP-Free Transit Packaging
10. Optimer Pharmaceuticals Reports Second Quarter 2012 Financial Results
11. MAP Pharmaceuticals, Inc. Announces Proposed Public Offering of Common Stock
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... , July 30, 2015 AACC ... to the 2015 AACC Annual Meeting & Clinical ... from July 26–30. The meeting showcased revolutionary advancements ... the ability of healthcare providers to diagnose patients ... effective medical treatment. As of ...
(Date:7/30/2015)... ... July 30, 2015 , ... Leading regenerative veterinary medicine company, ... canine osteoarthritis stem cell product, currently under development for FDA approval. The product ... marketed in the US by Aratana. This product, termed AT-016, is an allogeneic ...
(Date:7/30/2015)... 2015 HIGHLIGHTS:Q2 2015 Results (all ... , Reported sales were $697 million compared to $701 ... organically by 8%, and changes in foreign currency exchange ... by 1%. , By business unit, organic sales ... 11% in SAFC Commercial. , Reported diluted EPS ...
(Date:7/29/2015)... July 30, 2015 Sanofi, ... publie ses résultats pour le premier semestre 2015. ... les résultats. Visionner l,interview vidéo et ... Au sommaire de l,interview :  ... Moteurs de croissance - Diabète ...
Breaking Biology Technology:Innovative Research on Cancer, Heart Disease, and Infectious Diseases Draws More than 17,500 Attendees to 2015 AACC Annual Meeting 2Innovative Research on Cancer, Heart Disease, and Infectious Diseases Draws More than 17,500 Attendees to 2015 AACC Annual Meeting 3Innovative Research on Cancer, Heart Disease, and Infectious Diseases Draws More than 17,500 Attendees to 2015 AACC Annual Meeting 4VetStem Biopharma Successfully Completes Large Milestone Efficacy Study for its Flagship Canine Osteoarthritis Stem Cell Product 2VetStem Biopharma Successfully Completes Large Milestone Efficacy Study for its Flagship Canine Osteoarthritis Stem Cell Product 3Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 2Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 3Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 4Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 5Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 6Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 7Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 8Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 9Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 10Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 11Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 12Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 13Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 14Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 15Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 16Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 17Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 18Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 19Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 20
... poised to take their business to the $1 million annual ... prize packages, and business mentoring when the Make Mine ... here May 21. , ,The all-day event, which will take ... to women-owned businesses, including those in the technology and life ...
... Hanlon sees a lot of parallels between riding a motorcycle and ... has skinned his knees attempting to do both. , ,Hanlon will ... during the Wisconsin Alumni Research Foundation's Gilson Series ... managing an emerging-growth company. , ,While he figures to be speaking ...
... capital in more deals in 2006, but the improvement was ... Ernst & Young, LLP and Dow Jones VentureOne ... 2006, including a $12 .5 million round by NimbleGen ... a total of $58.47 million. The total, up from the ...
Cached Biology Technology:Women's entrepreneurial event set for May 21 2Motorcycling entrepreneur to speak in Madison on success, failure, capital 2Motorcycling entrepreneur to speak in Madison on success, failure, capital 3Wisconsin fares slightly better in venture capital chase 2Wisconsin fares slightly better in venture capital chase 3
(Date:7/31/2015)... Den 10. internationale konference om Genomik (ICG-10, ... - 25. oktober i Shenzhen , ... i år. Siden starten i 2006 er ICB blevet ... og er en af de mest dynamiske, entusiastiske og ... nylige gennembrud og fremskridt inden for ,omik,-forskning, som yderligere ...
(Date:7/31/2015)... China , 31 de julio de 2015 /PRNewswire/ ... Genómica (ICG-10,  www.icg-10.org ) del 22 al 25 de ... . La conferencia celebra su décimo aniversario ... ha convertido en una de las reuniones anuales más ... y es una de las conferencias científicas más dinámicas, ...
(Date:7/31/2015)... , 31 de julho de 2015 A ... www.icg-10.org ) será realizada pela BGI de 22-25 de outubro ... A conferência está celebrando seu 10 o. ... a ICG se tornou uma das reuniões mais influentes ... encontros científicos mais dinâmicos, entusiastas e prazerosos. ...
Breaking Biology News(10 mins):Den 10. internationale konference om Genomics (ICG-10) åbner i oktober 2La 10ª Conferencia Internacional sobre Genómica (ICG-10) comienza en octubre 2La 10ª Conferencia Internacional sobre Genómica (ICG-10) comienza en octubre 3A 10a. Conferência Internacional sobre Genômica (ICG-10) será em outubro 2A 10a. Conferência Internacional sobre Genômica (ICG-10) será em outubro 3
... forms of leukemia, who currently have no viable treatment ... types of cancer, according to a study conducted by ... & Science University (OHSU). The study, published in ... Journal of Medicine , isolated the molecular mutation that ...
... Two professors from the David Geffen School of Medicine at ... National Academy of Sciences in recognition of their distinguished and ... the academy is considered one of the highest honors presented ... Robert Oppenheimer, Thomas Edison, Orville Wright and Alexander Graham Bell. ...
... The large-scale expansion of agriculture in the Amazon through ... new study. Published today, 10 May, in IOP ... that deforestation will not only reduce the capacity of ... climate feedbacks that will decrease the productivity of pasture ...
Cached Biology News:Discovery pinpoints cause of 2 types of leukemia 2Discovery pinpoints cause of 2 types of leukemia 32 UCLA faculty elected to National Academy of Sciences 2No-win situation for agricultural expansion in the Amazon 2
... capable of dynamic scheduling, is designed to ... automation workcells easy for lab personnel, yet ... • Users create methods by ... can build a flowchart, you can write ...
... demands continue to grow, the need for ... has become necessary, especially when discerning very ... innovative C1si Confocal Microscope System gives you ... capability not available in conventional confocal systems, ...
... The TUNEL-based assay kit provides complete ... cells for convenient detection of DNA ... sections. The incorporation of BrdU in ... biotinylated or digoxigenylated methods. Results can ...
... your Ion Chromatography requirements, IonQuest will ... The newly developed conductivity detector has ... . In addition to the standard ... with other detectors, such as electrochemical, refractive ...
Biology Products: